In this round up we provide you with the biggest headlines and highlights from the IASLC World Conference on Lung Cancer (WCLC) the world’s largest meeting dedicated to lung cancer and other thoracic malignancies.
A Phase III trial involving the combination of immunotherapy and chemotherapy has seen significantly improved overall survival and progression-free survival in extensive-stage small-cell lung cancer patients.
In this review article from Future Oncology find out about the PACIFIC trial design as well as the future of immunotherapy combinations and biomarkers beyond PD-L1.
A combination of the targeted drug vistusertib with paclitaxel chemotherapy has shown promise in an early clinical trial, in patients with ovarian or lung cancer for whom all other treatments had failed.
In May and June several oncology drugs have been newly approved or been designated a new indication by the FDA.
The TAILORx study has demonstrated that most women with a specific early-stage breast cancer and midrange score on the Oncotype DX® test do not need chemotherapy after surgery.
In this new article published in Future Oncology, Ottoboni et al. report on the safety of a novel and recently FDA-approved polysorbate 80‒ and synthetic surfactant‒free intravenous formulation of the neurokinin 1 receptor antagonist aprepitant (HTX-019).
Results of a randomized clinical trial, presented at ASCO 2018, highlight the benefit of preoperative chemoradiotherapy for patients with pancreatic cancer that can be treated with surgery.
The PRODIGE 7 randomized study has demonstrated that for advanced colorectal cancer patients, hyperthermic intra-peritoneal chemotherapy delivered to the abdomen during surgery, may not be necessary.
Analysis of cancer registry data has revealed that women with head and neck cancer were less likely to receive intensive chemotherapy and radiation compared to men.